Medivir AB (publ) (0GP7.L)

2.9267 -4.0733 (-58.19%) At close: 06:16PM BST

Medivir AB (publ)

Lunastigen 5
2nd Floor
Huddinge
Sweden
46 8 54 68 31 00
https://www.medivir.com

Sector(s): 
Industry: 
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jens Lindberg	Chief Executive Officer	7.82M	N/A	1971
Mr. Magnus Christensen	Chief Financial Officer	2.66M	N/A	1974
Mr. Fredrik Öberg	Chief Scientific Officer	N/A	N/A	1965
Ms. Pia Baumann	Chief Medical Officer	N/A	N/A	1966
Karin Tunblad	Senior Principal Scientist & MIV-818 Project Leader	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. The company was incorporated in 1987 and is based in Huddinge, Sweden.

Corporate governance

Medivir AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.